Form 4: Seres Therapeutics Director Acquires Stock Options

Kurt Graves, a Director at Seres Therapeutics, Inc., acquired stock options for 6,500 shares of common stock.

Summary

• Kurt Graves, a Director of Seres Therapeutics, Inc., acquired stock options on July 8, 2026.
• The options grant the right to buy 6,500 shares of common stock at an exercise price of $7.14 per share.
• These options are set to expire on July 7, 2036.
• The options vest and become exercisable on the earlier of July 8, 2027, or the day before the first annual stockholder meeting after July 8, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard stock option grant to a director, indicating potential long-term alignment but not immediate financial performance news.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price indicates a potential for future value appreciation.

Future Outlook

The acquisition of stock options by a director suggests a belief in the company's potential for future stock price appreciation, though no specific financial forecasts are provided in this filing.

Industry Context

StockSavvy.ai notes that insider option grants, particularly by directors, are common in the biotechnology sector as a means of aligning executive interests with shareholder value and incentivizing long-term performance.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive signal of management's commitment and belief in future growth, potentially aligning director interests with those of shareholders.

Key Dates

Keywords

Seres Therapeutics, Kurt Graves, stock options, SEC Form 4, insider trading, beneficial ownership, MCRB